$TVTX
Travere Therapeutics Inc Stock $tvtx

$tvtx Overview Financials Valuation SEC Filings Company Website

2023 Q2 Form 10-Q Financial Statement

#000143853323000024 Filed on May 04, 2023

Income Statement

Concept	2023 Q2	2023 Q1	2022 Q1
Revenue	$59.70M	$56.99M	$48.49M
YoY Change	10.21%	17.54%	2.28%
Cost Of Revenue	$1.990M	$5.125M	$2.138M
YoY Change	-2.97%	139.71%	29.97%
Gross Profit	$57.71M	$51.87M	$46.35M
YoY Change	10.73%	11.91%	1.28%
Gross Profit Margin	96.67%	91.01%	95.59%
Selling, General & Admin	$63.11M	$72.25M	$46.79M
YoY Change	19.13%	54.41%	27.22%
% of Gross Profit	109.37%	139.29%	100.95%
Research & Development	$66.99M	$7.500M	$56.61M
YoY Change	12.25%	-86.75%	18.07%
% of Gross Profit	116.09%	14.46%	122.14%
Depreciation & Amortization	$13.90M	$9.545M	$7.092M
YoY Change	71.48%	34.59%	16.76%
% of Gross Profit	24.09%	18.4%	15.3%
Operating Expenses	$145.3M	$79.75M	$103.4M
YoY Change	28.96%	-22.88%	22.04%
Operating Profit	-$87.58M	-$87.05M	-$66.13M
YoY Change	33.81%	31.63%	39.08%
Interest Expense	$2.217M	$2.900M	-$2.515M
YoY Change	-174.6%	-215.31%	-52.73%
% of Operating Profit
Other Income/Expense, Net	-$201.0K	$793.0K	-$9.789M
YoY Change	-86.85%	-108.1%	63.01%
Pretax Income	-$85.57M	-$86.25M	-$75.92M
YoY Change	27.75%	13.61%	41.76%
Income Tax	$65.00K	$78.00K	$100.0K
% Of Pretax Income
Net Earnings	-$85.63M	-$86.33M	-$75.97M
YoY Change	27.74%	13.64%	41.03%
Net Earnings / Revenue	-143.44%	-151.48%	-156.68%
Basic Earnings Per Share	-$1.13	-$1.27	-$1.20
Diluted Earnings Per Share	-$1.13	-$1.27	-$1.20
COMMON SHARES
Basic Shares Outstanding	74.61M shares	64.74M shares	63.13M shares
Diluted Shares Outstanding	76.00M shares	68.17M shares	63.13M shares

Balance Sheet

Concept	2023 Q2	2023 Q1	2022 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$491.3M	$440.4M	$529.7M
YoY Change	-3.43%	-16.85%	22.89%
Cash & Equivalents	$70.87M	$161.4M	$256.6M
Short-Term Investments	$420.5M	$279.1M	$273.1M
Other Short-Term Assets	$11.56M	$15.14M	$6.507M
YoY Change	24.49%	132.7%	-2.88%
Inventory	$18.77M	$6.712M	$6.521M
Prepaid Expenses
Receivables	$20.40M	$21.50M	$14.70M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$542.1M	$604.9M	$631.1M
YoY Change	-7.62%	-4.15%	11.69%
LONG-TERM ASSETS
Property, Plant & Equipment	$28.13M	$9.127M	$10.60M
YoY Change	179.06%	-13.91%	-9.36%
Goodwill	$900.0K	$900.0K	$900.0K
YoY Change	0.0%	0.0%	-3.85%
Intangibles	$154.5M	$162.9M	$153.3M
YoY Change	3.03%	6.24%
Long-Term Investments
YoY Change
Other Assets	$11.79M	$11.03M	$10.83M
YoY Change	9.09%	1.81%	-69.08%
Total Long-Term Assets	$194.4M	$203.3M	$197.3M
YoY Change	0.86%	3.05%	-0.85%
TOTAL ASSETS
Total Short-Term Assets	$542.1M	$604.9M	$631.1M
Total Long-Term Assets	$194.4M	$203.3M	$197.3M
Total Assets	$736.4M	$808.2M	$828.4M
YoY Change	-5.52%	-2.44%	8.42%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$19.92M	$16.73M	$18.43M
YoY Change	68.09%	-9.26%	22.83%
Accrued Expenses	$65.16M	$85.77M	$69.24M
YoY Change	-21.21%	23.87%	49.01%
Deferred Revenue	$10.24M	$10.98M	$14.23M
YoY Change	-18.07%	-22.87%
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$135.7M	$130.6M	$119.5M
YoY Change	9.01%	9.35%	40.53%
LONG-TERM LIABILITIES
Long-Term Debt	$376.4M	$376.0M	$374.3M
YoY Change	0.46%	0.44%	71.63%
Other Long-Term Liabilities	$107.8M	$9.068M	$10.35M
YoY Change	1022.64%	-12.39%	-76.02%
Total Long-Term Liabilities	$484.2M	$9.068M	$10.35M
YoY Change	4941.47%	-12.39%	-76.02%
TOTAL LIABILITIES
Total Short-Term Liabilities	$135.7M	$130.6M	$119.5M
Total Long-Term Liabilities	$484.2M	$9.068M	$10.35M
Total Liabilities	$619.9M	$619.1M	$620.3M
YoY Change	-0.46%	-0.19%	54.54%
SHAREHOLDERS EQUITY
Retained Earnings	-$1.186B	-$1.101B	-$811.7M
YoY Change	34.99%	35.58%	26.88%
Common Stock	$7.000K	$7.000K	$6.000K
YoY Change	16.67%	16.67%	-100.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$116.5M	$189.1M	$208.1M
YoY Change
Total Liabilities & Shareholders Equity	$736.4M	$808.2M	$828.4M
YoY Change	-5.52%	-2.44%	8.42%

Cashflow Statement

Concept	2023 Q2	2023 Q1	2022 Q1
OPERATING ACTIVITIES
Net Income	-$85.63M	-$86.33M	-$75.97M
YoY Change	27.74%	13.64%	41.03%
Depreciation, Depletion And Amortization	$13.90M	$9.545M	$7.092M
YoY Change	71.48%	34.59%	16.76%
Cash From Operating Activities	-$69.30M	-$81.12M	-$55.32M
YoY Change	88.28%	46.63%	108.96%
INVESTING ACTIVITIES
Capital Expenditures	$3.836M	$630.0K	$131.0K
YoY Change	-133.47%	380.92%	-97.09%
Acquisitions
YoY Change
Other Investing Activities	-$19.72M	-$9.072M	$38.43M
YoY Change	-28.65%	-123.61%	-139.85%
Cash From Investing Activities	-$23.55M	-$37.04M	$33.17M
YoY Change	-39.76%	-211.68%	-131.37%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	2.266M	$217.0M	$113.9M
YoY Change	172.68%	90.49%	-41.81%
NET CHANGE
Cash From Operating Activities	-69.30M	-$81.12M	-$55.32M
Cash From Investing Activities	-23.55M	-$37.04M	$33.17M
Cash From Financing Activities	2.266M	$217.0M	$113.9M
Net Change In Cash	-90.58M	$99.69M	$90.82M
YoY Change	20.66%	9.77%	43.11%
FREE CASH FLOW
Cash From Operating Activities	-$69.30M	-$81.12M	-$55.32M
Capital Expenditures	$3.836M	$630.0K	$131.0K
Free Cash Flow	-$73.13M	-$81.75M	-$55.45M
YoY Change	188.54%	47.42%	79.05%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2023Q1	dei	Entity Central Index Key EntityCentralIndexKey	0001438533
CY2023Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2023Q1	dei	Amendment Flag AmendmentFlag	false
CY2023Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
CY2023Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2021	us-gaap	Accounting Standards Update Extensible List AccountingStandardsUpdateExtensibleList	http://fasb.org/us-gaap/2022#AccountingStandardsUpdate202006CumulativeEffectPeriodOfAdoptionMember
CY2023Q1	dei	Document Type DocumentType	10-Q
CY2023Q1	dei	Document Quarterly Report DocumentQuarterlyReport	true
CY2023Q1	dei	Document Period End Date DocumentPeriodEndDate	2023-03-31
CY2023Q1	dei	Document Transition Report DocumentTransitionReport	false
CY2023Q1	dei	Entity File Number EntityFileNumber	001-36257
CY2023Q1	dei	Entity Registrant Name EntityRegistrantName	TRAVERE THERAPEUTICS, INC.
CY2023Q1	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2023Q1	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	27-4842691
CY2023Q1	dei	Entity Address Address Line1 EntityAddressAddressLine1	3611 Valley Centre Drive
CY2023Q1	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 300
CY2023Q1	dei	Entity Address City Or Town EntityAddressCityOrTown	San Diego
CY2023Q1	dei	Entity Address State Or Province EntityAddressStateOrProvince	CA
CY2023Q1	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	92130
CY2023Q1	dei	City Area Code CityAreaCode	888
CY2023Q1	dei	Local Phone Number LocalPhoneNumber	969-7879
CY2023Q1	dei	Security12b Title Security12bTitle	Common Stock, par value $0.0001 per share
CY2023Q1	dei	Trading Symbol TradingSymbol	TVTX
CY2023Q1	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2023Q1	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2023Q1	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2023Q1	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
CY2023Q1	dei	Entity Small Business EntitySmallBusiness	false
CY2023Q1	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2023Q1	dei	Entity Shell Company EntityShellCompany	false
CY2023Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	74607901	shares
CY2023Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	161376000	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	61688000	usd
CY2023Q1	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	400137000	usd
CY2022Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	388557000	usd
CY2023Q1	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	21537000	usd
CY2022Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	16646000	usd
CY2023Q1	us-gaap	Inventory Net InventoryNet	6712000	usd
CY2022Q4	us-gaap	Inventory Net InventoryNet	6922000	usd
CY2023Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	15142000	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	12624000	usd
CY2023Q1	us-gaap	Assets Current AssetsCurrent	604904000	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	486437000	usd
CY2023Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	9127000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	9049000	usd
CY2023Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	20289000	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	21000000	usd
CY2023Q1	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	162883000	usd
CY2022Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	145038000	usd
CY2023Q1	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	11028000	usd
CY2022Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	11061000	usd
CY2023Q1	us-gaap	Assets Assets	808231000	usd
CY2022Q4	us-gaap	Assets Assets	672585000	usd
CY2023Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	16727000	usd
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	17290000	usd
CY2023Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	85766000	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	95742000	usd
CY2023Q1	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	10975000	usd
CY2022Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	11976000	usd
CY2023Q1	us-gaap	Business Combination Contingent Consideration Liability Current BusinessCombinationContingentConsiderationLiabilityCurrent	6900000	usd
CY2022Q4	us-gaap	Business Combination Contingent Consideration Liability Current BusinessCombinationContingentConsiderationLiabilityCurrent	7000000	usd
CY2023Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	4545000	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	4433000	usd
CY2023Q1	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	5732000	usd
CY2022Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	5722000	usd
CY2023Q1	us-gaap	Liabilities Current LiabilitiesCurrent	130645000	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	142163000	usd
CY2023Q1	us-gaap	Convertible Debt Noncurrent ConvertibleDebtNoncurrent	375974000	usd
CY2022Q4	us-gaap	Convertible Debt Noncurrent ConvertibleDebtNoncurrent	375545000	usd
CY2023Q1	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	8778000	usd
CY2022Q4	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	10931000	usd
CY2023Q1	us-gaap	Business Combination Contingent Consideration Liability Noncurrent BusinessCombinationContingentConsiderationLiabilityNoncurrent	68300000	usd
CY2022Q4	us-gaap	Business Combination Contingent Consideration Liability Noncurrent BusinessCombinationContingentConsiderationLiabilityNoncurrent	64200000	usd
CY2023Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	26326000	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	27510000	usd
CY2023Q1	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	9068000	usd
CY2022Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	9385000	usd
CY2023Q1	us-gaap	Liabilities Liabilities	619091000	usd
CY2022Q4	us-gaap	Liabilities Liabilities	629734000	usd
CY2023Q1	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2022Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2022Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2023Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	20000000	shares
CY2023Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	20000000	shares
CY2023Q1	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2022Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2022Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2023Q1	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2023Q1	us-gaap	Preferred Stock Value PreferredStockValue	0	usd
CY2022Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	usd
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2023Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2023Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
CY2023Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	74586806	shares
CY2023Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	74586806	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	64290570	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	64290570	shares
CY2023Q1	us-gaap	Common Stock Value CommonStockValue	7000	usd
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	6000	usd
CY2023Q1	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	1291863000	usd
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	1059975000	usd
CY2023Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-1100554000	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-1014223000	usd
CY2023Q1	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-2176000	usd
CY2022Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-2907000	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	189140000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	42851000	usd
CY2023Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	808231000	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	672585000	usd
CY2023Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	56993000	usd
CY2022Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	48487000	usd
CY2023Q1	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	5125000	usd
CY2022Q1	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	2138000	usd
CY2023Q1	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	59913000	usd
CY2022Q1	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	56611000	usd
CY2023Q1	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	72245000	usd
CY2022Q1	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	46788000	usd
CY2023Q1	tvtx	Changein Fair Valueof Contingent Consideration ChangeinFairValueofContingentConsideration	6756000	usd
CY2022Q1	tvtx	Changein Fair Valueof Contingent Consideration ChangeinFairValueofContingentConsideration	9080000	usd
CY2023Q1	us-gaap	Costs And Expenses CostsAndExpenses	144039000	usd
CY2022Q1	us-gaap	Costs And Expenses CostsAndExpenses	114617000	usd
CY2023Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-87046000	usd
CY2022Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-66130000	usd
CY2023Q1	us-gaap	Investment Income Interest InvestmentIncomeInterest	3646000	usd
CY2022Q1	us-gaap	Investment Income Interest InvestmentIncomeInterest	278000	usd
CY2023Q1	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	-2940000	usd
CY2022Q1	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	-2515000	usd
CY2023Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	87000	usd
CY2022Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	26000	usd
CY2023Q1	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0	usd
CY2022Q1	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-7578000	usd
CY2023Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	793000	usd
CY2022Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-9789000	usd
CY2023Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-86253000	usd
CY2022Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-75919000	usd
CY2023Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	78000	usd
CY2022Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	52000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-86331000	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-75971000	usd
CY2023Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.27
CY2023Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.27
CY2022Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.20
CY2022Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.20
CY2023Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	68174099	shares
CY2023Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	68174099	shares
CY2022Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	63132841	shares
CY2022Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	63132841	shares
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-86331000	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-75971000	usd
CY2023Q1	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	-566000	usd
CY2022Q1	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	71000	usd
CY2023Q1	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	1297000	usd
CY2022Q1	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	-1204000	usd
CY2023Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-85600000	usd
CY2022Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-77104000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	42851000	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	302112000	usd
CY2023Q1	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	13325000	usd
CY2022Q1	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	7935000	usd
CY2023Q1	us-gaap	Stock Granted During Period Value Sharebased Compensation Gross StockGrantedDuringPeriodValueSharebasedCompensationGross	2296000	usd
CY2022Q1	us-gaap	Stock Granted During Period Value Sharebased Compensation Gross StockGrantedDuringPeriodValueSharebasedCompensationGross	122000	usd
CY2023Q1	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	439000	usd
CY2022Q1	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	251000	usd
CY2023Q1	tvtx	Pre Funded Common Stock Warrants Net Of Issuance Costs PreFundedCommonStockWarrantsNetOfIssuanceCosts	1600000	usd
CY2023Q1	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	24630000	usd
CY2023Q1	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	-566000	usd
CY2022Q1	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	71000	usd
CY2023Q1	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	1297000	usd
CY2022Q1	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-1204000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-86331000	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-75971000	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	189140000	usd
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	208141000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-86331000	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-75971000	usd
CY2023Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	9545000	usd
CY2022Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	7092000	usd
CY2023Q1	us-gaap	Share Based Compensation ShareBasedCompensation	13764000	usd
CY2022Q1	us-gaap	Share Based Compensation ShareBasedCompensation	8186000	usd
CY2023Q1	tvtx	Net Changein Fair Valueof Contingent Consideration NetChangeinFairValueofContingentConsideration	6756000	usd
CY2022Q1	tvtx	Net Changein Fair Valueof Contingent Consideration NetChangeinFairValueofContingentConsideration	9080000	usd
CY2023Q1	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	-2289000	usd
CY2022Q1	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	-2075000	usd
CY2023Q1	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0	usd
CY2022Q1	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-7578000	usd
CY2023Q1	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	488000	usd
CY2022Q1	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-2112000	usd
CY2023Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	4891000	usd
CY2022Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-1241000	usd
CY2023Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	513000	usd
CY2022Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	157000	usd
CY2023Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	2350000	usd
CY2022Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-648000	usd
CY2023Q1	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-627000	usd
CY2022Q1	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-4606000	usd
CY2023Q1	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	-9611000	usd
CY2022Q1	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	-4413000	usd
CY2023Q1	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-3844000	usd
CY2022Q1	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-2146000	usd
CY2023Q1	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	-238000	usd
CY2022Q1	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	-1889000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-81117000	usd
CY2022Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-55320000	usd
CY2023Q1	us-gaap	Proceeds From Sale And Maturity Of Available For Sale Securities ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities	94118000	usd
CY2022Q1	us-gaap	Proceeds From Sale And Maturity Of Available For Sale Securities ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities	64715000	usd
CY2023Q1	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	103190000	usd
CY2022Q1	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	26283000	usd
CY2023Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	630000	usd
CY2022Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	131000	usd
CY2023Q1	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	27337000	usd
CY2022Q1	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	5136000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-37039000	usd
CY2022Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	33165000	usd
CY2023Q1	tvtx	Payment Of Guaranteed Minimum Royalty PaymentOfGuaranteedMinimumRoyalty	525000	usd
CY2022Q1	tvtx	Payment Of Guaranteed Minimum Royalty PaymentOfGuaranteedMinimumRoyalty	525000	usd
CY2023Q1	us-gaap	Payment For Contingent Consideration Liability Financing Activities PaymentForContingentConsiderationLiabilityFinancingActivities	604000	usd
CY2022Q1	us-gaap	Payment For Contingent Consideration Liability Financing Activities PaymentForContingentConsiderationLiabilityFinancingActivities	667000	usd
CY2023Q1	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	0	usd
CY2022Q1	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	316250000	usd
CY2023Q1	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	0	usd
CY2022Q1	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	9488000	usd
CY2023Q1	us-gaap	Repayments Of Convertible Debt RepaymentsOfConvertibleDebt	0	usd
CY2022Q1	us-gaap	Repayments Of Convertible Debt RepaymentsOfConvertibleDebt	211324000	usd
CY2023Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	2296000	usd
CY2022Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	122000	usd
CY2023Q1	us-gaap	Proceeds From Issuance Of Warrants ProceedsFromIssuanceOfWarrants	24630000	usd
CY2022Q1	us-gaap	Proceeds From Issuance Of Warrants ProceedsFromIssuanceOfWarrants	0	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	216996000	usd
CY2022Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	113913000	usd
CY2023Q1	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	848000	usd
CY2022Q1	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-939000	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	99688000	usd
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	90819000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	61688000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	165753000	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	161376000	usd
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	256572000	usd
CY2023Q1	us-gaap	Nature Of Operations NatureOfOperations	DESCRIPTION OF BUSINESS<div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#006ebf;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Organization and Description of Business</span></div><div style="margin-bottom:6pt;margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Travere Therapeutics, Inc. (“we”, “our”, “us”, “Travere” and the “Company”) refers to Travere Therapeutics, Inc., a Delaware corporation, as well as its subsidiaries. Travere is a fully integrated biopharmaceutical company headquartered in San Diego, California focused on identifying, developing and delivering life-changing therapies to people living with rare kidney, liver, and metabolic diseases. The Company regularly evaluates and, where appropriate, acts on opportunities to expand its product pipeline through licenses and acquisitions of products in areas that will serve patients with serious </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial Narrow',sans-serif;font-size:9pt;font-weight:400;line-height:120%">unmet medical need</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> and that the Company believes offer attractive growth characteristics.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#006ebf;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">FILSPARI™ (sparsentan)</span></div><div style="margin-bottom:6pt;margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:9pt;font-weight:400;line-height:120%">On February 17, 2023, the FDA granted accelerated approval of FILSPARI™ (sparsentan) to reduce proteinuria in adults with primary IgAN at risk of rapid disease progression, generally at UPCR ≥1.5 gram/gram. FILSPARI, a once-daily, oral medication is designed to selectively target two critical pathways (endothelin 1 and angiotensin-II) in the disease progression of IgAN. </span></div><div style="margin-bottom:6pt;margin-top:9pt;text-align:justify"><span style="color:#666666;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Clinical-Stage Programs:</span></div><div style="margin-bottom:6pt;margin-top:3pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial Narrow',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The continued approval of FILSPARI for IgAN may be contingent upon confirmation of a clinical benefit in the Company's ongoing Phase 3 clinical trial of sparsentan for the treatment of IgAN (the "PROTECT Study"), which is designed to demonstrate whether FILSPARI slows kidney function decline. Topline results from the two-year confirmatory endpoints in the PROTECT Study are expected in the fourth quarter of 2023 and are intended to support traditional approval of FILSPARI.</span></div><div style="margin-bottom:6pt;margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Sparsentan remains a novel investigational product candidate which has been granted Orphan Drug Designation for the treatment of focal segmental glomerulosclerosis (FSGS) in the U.S. and Europe. The double-blind portion of the Phase 3 study of sparsentan for FSGS has recently concluded and, following release of the top-line data from the study which showed that the study did not meet its primary endpoint, the Company is conducting further analyses of the data and is preparing to engage with regulators to explore a potential path forward toward a potential regulatory submission in FSGS.</span></div><div style="margin-bottom:6pt;margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Pegtibatinase (</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial Narrow',sans-serif;font-size:9pt;font-weight:400;line-height:120%">TVT-058) is a novel investigational human enzyme replacement candidate being evaluated for the treatment of classical homocystinuria (HCU). Pegtibatinase has been granted Rare Pediatric Disease, Fast Track and Breakthrough Therapy designations by the FDA, as well as orphan drug designation in the United States and European Union. Pegtibatinase is currently being evaluated in the Phase 1/2 COMPOSE Study to assess its safety, tolerability, pharmacokinetics, pharmacodynamics and clinical effects in patients with classical HCU. The Company</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> acquired pegtibatinase as part of the November 2020 acquisition of Orphan Technologies Limited.</span></div><div style="margin-bottom:6pt;margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Chenodal (chenodeoxycholic acid or CDCA) is a naturally occurring bile acid that is approved for the treatment of people with radiolucent stones in the gallbladder. In September 2022, the Company was granted Fast Track Designation by the FDA for the investigation of Chenodal for cerebrotendinous xanthomatosis (CTX). In January 2020, the Company randomized the first patients in its Phase 3 RESTORE Study to evaluate the effects of Chenodal in adult and pediatric patients with CTX, and the study enrollment remains open. The pivotal study is intended to support an NDA submission for marketing authorization of Chenodal for CTX in the United States. </span></div><div style="margin-bottom:6pt;margin-top:9pt"><span style="color:#666666;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Preclinical Programs:</span></div><div style="margin-bottom:6pt;margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company is a participant in a Cooperative Research and Development Agreement ("CRADA"), which forms a multi-stakeholder approach to pool resources with leading experts, and incorporate the patient perspective early in the therapeutic identification and development process. The Company is partnering with the National Institutes of Health’s National Center for Advancing Translational Sciences ("NCATS") and a leading patient advocacy organization, Alagille Syndrome Alliance, aimed at the identification of potential small molecule therapeutics for Alagille syndrome ("ALGS"). There are no treatment options currently approved for ALGS.</span></div><div style="margin-bottom:6pt;margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company is party to a collaboration agreement with PharmaKrysto Limited and their early-stage cystinuria discovery program, whereby the Company is responsible for funding all research and development expenses for the pre-clinical activities associated with the cystinuria program.</span></div><div style="margin-bottom:6pt;margin-top:9pt;text-align:justify"><span style="color:#666666;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Commercial Products:</span></div><div style="margin-bottom:6pt;margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:9pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:15.42pt">Thiola</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> and Thiola EC</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> (tiopronin tablets) are approved in the United States for the prevention of cystine (kidney) stone formation in patients with severe homozygous cystinuria.</span></div><div style="margin-bottom:6pt;margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:9pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:15.42pt">Cholbam</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> (cholic acid capsules) is approved in the United States for the treatment of bile acid synthesis disorders due to single enzyme defects and is further indicated for adjunctive treatment of patients with peroxisomal disorders.</span></div>•Chenodal (chenodiol tablets) is approved in the United States for the treatment of patients suffering from gallstones in whom surgery poses an unacceptable health risk due to disease or advanced age.
CY2023Q1	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	5125000	usd
CY2022Q1	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	2138000	usd
CY2023Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	7500000	usd
CY2023Q1	tvtx	Number Of Phase One Half Clinical Trials NumberOfPhaseOneHalfClinicalTrials	1	clinicaltrial
CY2023Q1	tvtx	Number Of Phase3 Clinical Trials In Process NumberOfPhase3ClinicalTrialsInProcess	3	clinicaltrial
CY2023Q1	us-gaap	Revenue Performance Obligation Description Of Timing RevenuePerformanceObligationDescriptionOfTiming	For FILSPARI, sales are recognized upon delivery of the product to the specialty pharmacies. The Company receives payments from its FILSPARI sales based on terms that are generally 30 days from shipment of the product to the specialty pharmacy. For the Company's other products, product sales are recognized upon delivery to the patient. The Company receives payments from sales of its other products, primarily through third party payers, based on terms that generally are within 30 days of delivery of product to the patient.
CY2023Q1	us-gaap	Contract With Customer Performance Obligation Satisfied In Previous Period ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod	400000	usd
CY2022Q1	us-gaap	Contract With Customer Performance Obligation Satisfied In Previous Period ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod	100000	usd
CY2023Q1	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	400137000	usd
CY2022Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	388557000	usd
CY2023Q1	tvtx	Debt Securities Availableforsale Amortized Cost Basis Current DebtSecuritiesAvailableforsaleAmortizedCostBasisCurrent	280387000	usd
CY2023Q1	tvtx	Debt Securities Available For Sale Unrealized Gain Current DebtSecuritiesAvailableForSaleUnrealizedGainCurrent	9000	usd
CY2023Q1	tvtx	Debt Securities Available For Sale Unrealized Loss Current DebtSecuritiesAvailableForSaleUnrealizedLossCurrent	1339000	usd
CY2023Q1	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	279057000	usd
CY2023Q1	tvtx	Debt Securities Availableforsale Amortized Cost Basis Noncurrent DebtSecuritiesAvailableforsaleAmortizedCostBasisNoncurrent	121408000	usd
CY2023Q1	tvtx	Debt Securities Available For Sale Unrealized Gain Noncurrent DebtSecuritiesAvailableForSaleUnrealizedGainNoncurrent	226000	usd
CY2022Q4	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger	112420000	usd
CY2022Q4	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Accumulated Loss DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss	1036000	usd
CY2022Q4	us-gaap	Debt Securities Available For Sale Unrealized Loss Position DebtSecuritiesAvailableForSaleUnrealizedLossPosition	360741000	usd
CY2023Q1	tvtx	Debt Securities Available For Sale Unrealized Loss Noncurrent DebtSecuritiesAvailableForSaleUnrealizedLossNoncurrent	554000	usd
CY2023Q1	us-gaap	Available For Sale Securities Debt Securities Noncurrent AvailableForSaleSecuritiesDebtSecuritiesNoncurrent	121080000	usd
CY2023Q1	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	401795000	usd
CY2023Q1	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	235000	usd
CY2023Q1	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	1893000	usd
CY2023Q1	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	400137000	usd
CY2022Q4	tvtx	Debt Securities Availableforsale Amortized Cost Basis Current DebtSecuritiesAvailableforsaleAmortizedCostBasisCurrent	287615000	usd
CY2022Q4	tvtx	Debt Securities Available For Sale Unrealized Gain Current DebtSecuritiesAvailableForSaleUnrealizedGainCurrent	2000	usd
CY2022Q4	tvtx	Debt Securities Available For Sale Unrealized Loss Current DebtSecuritiesAvailableForSaleUnrealizedLossCurrent	2091000	usd
CY2022Q4	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	285526000	usd
CY2022Q4	tvtx	Debt Securities Availableforsale Amortized Cost Basis Noncurrent DebtSecuritiesAvailableforsaleAmortizedCostBasisNoncurrent	103897000	usd
CY2022Q4	tvtx	Debt Securities Available For Sale Unrealized Gain Noncurrent DebtSecuritiesAvailableForSaleUnrealizedGainNoncurrent	39000	usd
CY2022Q4	tvtx	Debt Securities Available For Sale Unrealized Loss Noncurrent DebtSecuritiesAvailableForSaleUnrealizedLossNoncurrent	905000	usd
CY2022Q4	us-gaap	Available For Sale Securities Debt Securities Noncurrent AvailableForSaleSecuritiesDebtSecuritiesNoncurrent	103031000	usd
CY2022Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	391512000	usd
CY2022Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	41000	usd
CY2022Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	2996000	usd
CY2022Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	388557000	usd
CY2023Q1	us-gaap	Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities	94100000	usd
CY2023Q1	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	103200000	usd
CY2022Q1	us-gaap	Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities	64700000	usd
CY2022Q1	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	26300000	usd
CY2023Q1	us-gaap	Interest Receivable Current InterestReceivableCurrent	2000000	usd
CY2022Q4	us-gaap	Interest Receivable Current InterestReceivableCurrent	1900000	usd
CY2023Q1	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months	264491000	usd
CY2023Q1	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss	1467000	usd
CY2023Q1	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger	73386000	usd
CY2023Q1	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Accumulated Loss DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss	426000	usd
CY2023Q1	us-gaap	Debt Securities Available For Sale Unrealized Loss Position DebtSecuritiesAvailableForSaleUnrealizedLossPosition	337877000	usd
CY2023Q1	us-gaap	Debt Securities Available For Sale Unrealized Loss Position Accumulated Loss DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss	1893000	usd
CY2022Q4	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months	248321000	usd
CY2022Q4	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss	1960000	usd
CY2023Q1	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	5791000	usd
CY2022Q4	us-gaap	Debt Securities Available For Sale Unrealized Loss Position Accumulated Loss DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss	2996000	usd
CY2023Q1	tvtx	Debt Securities Available For Sale Unrealized Loss Position Amortized Cost DebtSecuritiesAvailableForSaleUnrealizedLossPositionAmortizedCost	339800000	usd
CY2022Q4	tvtx	Debt Securities Available For Sale Unrealized Loss Position Amortized Cost DebtSecuritiesAvailableForSaleUnrealizedLossPositionAmortizedCost	363700000	usd
CY2023Q1	us-gaap	Lessee Operating Lease Renewal Term LesseeOperatingLeaseRenewalTerm	P5Y
CY2023Q1	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	4754000	usd
CY2023Q1	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	6501000	usd
CY2023Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	6673000	usd
CY2023Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	6889000	usd
CY2023Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	7064000	usd
CY2023Q1	tvtx	Lessee Operating Lease Liability Payments Due After Year Four LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour	4781000	usd
CY2023Q1	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	36662000	usd
CY2023Q1	us-gaap	Operating Lease Liability OperatingLeaseLiability	30871000	usd
CY2023Q1	tvtx	Operating Lease Incentive Tenant Improvements OperatingLeaseIncentiveTenantImprovements	5329000	usd
CY2023Q1	tvtx	Straight Line Lease Expense In Excess Of Cash Payments StraightLineLeaseExpenseInExcessOfCashPayments	5253000	usd
CY2023Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	20289000	usd
CY2023Q1	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P5Y4M24D
CY2022Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P5Y8M12D
CY2023Q1	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.0648
CY2022Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.0648
CY2023Q1	us-gaap	Operating Lease Expense OperatingLeaseExpense	1200000	usd
CY2022Q1	us-gaap	Operating Lease Expense OperatingLeaseExpense	1200000	usd
CY2023Q1	us-gaap	Cash And Cash Equivalents Fair Value Disclosure CashAndCashEquivalentsFairValueDisclosure	161376000	usd
CY2023Q1	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	400137000	usd
CY2023Q1	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	561513000	usd
CY2023Q1	us-gaap	Business Combination Contingent Consideration Liability BusinessCombinationContingentConsiderationLiability	75200000	usd
CY2023Q1	us-gaap	Liabilities Fair Value Disclosure LiabilitiesFairValueDisclosure	75200000	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents Fair Value Disclosure CashAndCashEquivalentsFairValueDisclosure	61688000	usd
CY2022Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	388557000	usd
CY2022Q4	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	450245000	usd
CY2022Q4	us-gaap	Business Combination Contingent Consideration Liability BusinessCombinationContingentConsiderationLiability	71200000	usd
CY2022Q4	us-gaap	Liabilities Fair Value Disclosure LiabilitiesFairValueDisclosure	71200000	usd
CY2023Q1	us-gaap	Number Of Businesses Acquired NumberOfBusinessesAcquired	2	business
CY2022Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	302935000	usd
CY2023Q1	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	167820000	usd
CY2022Q4	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	71200000	usd
CY2021Q4	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	67100000	usd
CY2023Q1	tvtx	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Change In Fair Value FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityChangeInFairValue	6756000	usd
CY2022Q1	tvtx	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Change In Fair Value FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityChangeInFairValue	9080000	usd
CY2023Q1	tvtx	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Settlements Accrued FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlementsAccrued	2756000	usd
CY2022Q1	tvtx	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Settlements Accrued FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlementsAccrued	2680000	usd
CY2023Q1	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	75200000	usd
CY2022Q1	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	73500000	usd
CY2023Q1	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	329767000	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	158833000	usd
CY2023Q1	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	161947000	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	144102000	usd
CY2022Q4	us-gaap	Goodwill Goodwill	900000	usd
CY2023Q1	us-gaap	Goodwill Goodwill	900000	usd
CY2023Q1	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	8987000	usd
CY2022Q1	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	6556000	usd
CY2022Q1	tvtx	Debt Instrument Repurchase Amount Including Accrued And Unpaid Interest DebtInstrumentRepurchaseAmountIncludingAccruedAndUnpaidInterest	213800000	usd
CY2022Q1	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-7600000	usd
CY2022Q1	us-gaap	Write Off Of Deferred Debt Issuance Cost WriteOffOfDeferredDebtIssuanceCost	3400000	usd
CY2023Q1	us-gaap	Interest Expense InterestExpense	2900000	usd
CY2022Q1	us-gaap	Interest Expense InterestExpense	2500000	usd
CY2023Q1	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	26839000	usd
CY2022Q4	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	35267000	usd
CY2023Q1	tvtx	Accrued Liabilities Researchand Development Current AccruedLiabilitiesResearchandDevelopmentCurrent	24909000	usd
CY2022Q4	tvtx	Accrued Liabilities Researchand Development Current AccruedLiabilitiesResearchandDevelopmentCurrent	26070000	usd
CY2023Q1	tvtx	Government Rebates Payable GovernmentRebatesPayable	11451000	usd
CY2022Q4	tvtx	Government Rebates Payable GovernmentRebatesPayable	13486000	usd
CY2023Q1	tvtx	Accrued Liabilities Selling Generaland Administrative Current AccruedLiabilitiesSellingGeneralandAdministrativeCurrent	9064000	usd
CY2022Q4	tvtx	Accrued Liabilities Selling Generaland Administrative Current AccruedLiabilitiesSellingGeneralandAdministrativeCurrent	8791000	usd
CY2023Q1	us-gaap	Accrued Royalties Current AccruedRoyaltiesCurrent	7218000	usd
CY2023Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.27
CY2022Q4	us-gaap	Accrued Royalties Current AccruedRoyaltiesCurrent	7755000	usd
CY2023Q1	tvtx	Accrued Liabilities Miscellaneous AccruedLiabilitiesMiscellaneous	6285000	usd
CY2022Q4	tvtx	Accrued Liabilities Miscellaneous AccruedLiabilitiesMiscellaneous	4373000	usd
CY2023Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	85766000	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	95742000	usd
CY2023Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	68174099	shares
CY2023Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	68174099	shares
CY2023Q1	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-86331000	usd
CY2023Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-86331000	usd
CY2023Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.27
CY2022Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	63132841	shares
CY2022Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	63132841	shares
CY2022Q1	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-75971000	usd
CY2022Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-75971000	usd
CY2022Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.20
CY2022Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.20
CY2023Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	25523529	shares
CY2022Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	20100996	shares
CY2023Q1	us-gaap	Long Term Purchase Commitment Amount LongTermPurchaseCommitmentAmount	36300000	usd
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	7400000	shares
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	20.65
CY2023Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	13764000	usd
CY2022Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	8186000	usd
CY2023Q1	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	3077000	usd
CY2022Q4	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	3627000	usd
CY2023Q1	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	3635000	usd
CY2022Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	3295000	usd
CY2023Q1	us-gaap	Inventory Net InventoryNet	6712000	usd
CY2022Q4	us-gaap	Inventory Net InventoryNet	6922000	usd
CY2023Q1	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	21500000	usd
CY2022Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	16600000	usd

Files In Submission

Name	View Source	Status
FilingSummary.xml	Edgar Link	unprocessable
tvtx-20230331_htm.xml	Edgar Link	completed
0001438533-23-000024-index-headers.html	Edgar Link	pending
0001438533-23-000024-index.html	Edgar Link	pending
0001438533-23-000024.txt	Edgar Link	pending
0001438533-23-000024-xbrl.zip	Edgar Link	pending
ex03312023102inrigemployme.htm	Edgar Link	pending
ex03312023311.htm	Edgar Link	pending
ex03312023312.htm	Edgar Link	pending
ex03312023321.htm	Edgar Link	pending
ex03312023322.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
R9999.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
tvtx-20230331.htm	Edgar Link	pending
tvtx-20230331.xsd	Edgar Link	pending
tvtx-20230331_g1.jpg	Edgar Link	pending
tvtx-20230331_def.xml	Edgar Link	unprocessable
tvtx-20230331_lab.xml	Edgar Link	unprocessable
tvtx-20230331_pre.xml	Edgar Link	unprocessable
tvtx-20230331_cal.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$TVTX
Travere Therapeutics Inc Stock $tvtx

2023 Q2 Form 10-Q Financial Statement

#000143853323000024 Filed on May 04, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$TVTX Travere Therapeutics Inc Stock $tvtx

2023 Q2 Form 10-Q Financial Statement

#000143853323000024 Filed on May 04, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$TVTX
Travere Therapeutics Inc Stock $tvtx